Michelle Min, MD, MS, reviewed best practices for managing cutaneous lupus and discussed emerging therapies practitioners ...
Real-world data from Fall Clinical 2026 reveal widespread treatment dissatisfaction, anxiety, and steroid hesitancy among ...
Dr Hamzavi discussed how to navigate conversations with patients with HS regarding common misconceptions, expectations with ...
Post hoc ICONIC phase 3 data show GLP-1 medications do not affect the efficacy, safety, or pharmacokinetics of icotrokinra in ...
Tralokinumab for AD was associated with sustained improvements in disease severity and no new safety signals at 12 months in a real-life study.
Congenital TORCH infections appear to be associated with an increased risk for intellectual disability and autism.
The use of vibration anesthesia in patients undergoing cryotherapy was associated with pain reductions when compared with cryotherapy alone.
The FDA has expanded the approval of Rhapsido (remibrutinib) to include symptomatic dermographism in adults inadequately controlled by H1 antihistamines, backed by phase 3 RemIND trial data.
The only baseline characteristic that predicted super response to topical ruxolitinib in patients with nonsegmental vitiligo was disease activity.
Creams, sprays and washes that promise relief from genital herpes are easy to order online, but none of them are FDA-approved.
BRAVE-AA-PEDS data presented at FC26 show baricitinib maintained significant hair regrowth through 76 weeks in adolescents ...
An active acupressure intervention offers clinical benefits for patients with rosacea when combined with pharmacotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results